Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer

Схожие документы

• Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
  по: Dowsett, Mitch, et al.
  Опубликовано: (2018)
• Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors
  по: Sestak, Ivana, et al.
  Опубликовано: (2016)
• Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
  по: Sestak, Ivana, et al.
  Опубликовано: (2013)
• Markers for the identification of late breast cancer recurrence
  по: Sestak, Ivana, et al.
  Опубликовано: (2015)
• Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
  по: Buus, Richard, et al.
  Опубликовано: (2016)